{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:00:59Z","timestamp":1790510459971,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Centre National de la Recherche Scientifique, the Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale"},{"name":"University Pierre and Marie Curie of Paris"},{"name":"University of Strasbourg, the Centre Hospitalier et Universitaire de Strasbourg"},{"name":"Fondation de France, the French Ministry of Research, and the Agence Nationale pour la Recherche","award":["ANR-12-BSV1-0015-01"],"award-info":[{"award-number":["ANR-12-BSV1-0015-01"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.phrs.2018.09.009","type":"journal-article","created":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T09:54:48Z","timestamp":1536486888000},"page":"33-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Serotonin contribution to cardiac valve degeneration: new insights for novel therapies?"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0613-3803","authenticated-orcid":false,"given":"Estelle","family":"Ayme-Dietrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0684-8809","authenticated-orcid":false,"given":"Roland","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Philippe","family":"Mazzucotelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Monassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"May (3)","key":"10.1016\/j.phrs.2018.09.009_bib0005","first-page":"348","article-title":"Mitral and aortic valvular disease associated with benfluorex use","volume":"20","author":"Etienne","year":"2011","journal-title":"J. Heart Valve Dis."},{"issue":"February","key":"10.1016\/j.phrs.2018.09.009_bib0010","article-title":"Benfluorex-induced severe primary tricuspid and mitral regurgitation requiring a double-valve replacement","author":"Eug\u00e8ne","year":"2018","journal-title":"Eur. J. Card.-Thor. Surg."},{"issue":"August (8)","key":"10.1016\/j.phrs.2018.09.009_bib0015","article-title":"Drug-induced- or rheumatic- valvular heart disease in patients exposed to benfluorex?","volume":"11","author":"Le","year":"2016","journal-title":"PLoS One"},{"issue":"May (5)","key":"10.1016\/j.phrs.2018.09.009_bib0020","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1084\/jem.20101629","article-title":"Platelet-derived serotonin links vascular disease and tissue fibrosis","volume":"208","author":"Dees","year":"2011","journal-title":"J. Exp. Med."},{"issue":"October (10)","key":"10.1016\/j.phrs.2018.09.009_bib0025","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nm764","article-title":"Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension","volume":"8","author":"Launay","year":"2002","journal-title":"Nat. Med."},{"issue":"January (1)","key":"10.1016\/j.phrs.2018.09.009_bib0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/CIRCRESAHA.108.180976","article-title":"Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy","volume":"104","author":"Jaffr\u00e9","year":"2009","journal-title":"Circ. Res."},{"issue":"August","key":"10.1016\/j.phrs.2018.09.009_bib0035","article-title":"Serotonergic 5-HT2B receptors in mitral valvulopathy: bone marrow mobilization of endothelial progenitors","author":"Ayme-Dietrich","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"November (12)","key":"10.1016\/j.phrs.2018.09.009_bib0040","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/nm.2490","article-title":"Stimulating healthy tissue regeneration by targeting the 5-HT2B receptor in chronic liver disease","volume":"17","author":"Ebrahimkhani","year":"2011","journal-title":"Nat. Med."},{"issue":"January (5603)","key":"10.1016\/j.phrs.2018.09.009_bib0045","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1126\/science.1078197","article-title":"Synthesis of serotonin by a second tryptophan hydroxylase isoform","volume":"299","author":"Walther","year":"2003","journal-title":"Science (New York, N.Y.)"},{"issue":"November (1)","key":"10.1016\/j.phrs.2018.09.009_bib0050","first-page":"64","article-title":"Life without peripheral serotonin: insights from tryptophan hydroxylase 1 knockout mice reveal the existence of Paracrine\/Autocrine serotonergic networks","volume":"4","author":"Amireault","year":"2012","journal-title":"ACS Chem. Neurosci."},{"issue":"June (6)","key":"10.1016\/j.phrs.2018.09.009_bib0055","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.tips.2018.03.004","article-title":"Peripheral serotonin synthesis as a new drug target","volume":"39","author":"Matthes","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"issue":"July (1)","key":"10.1016\/j.phrs.2018.09.009_bib0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0163-7258(02)00234-6","article-title":"Therapeutic and adverse actions of serotonin transporter substrates","volume":"95","author":"Rothman","year":"2002","journal-title":"Pharmacol. Ther."},{"issue":"April (2\u20133)","key":"10.1016\/j.phrs.2018.09.009_bib0065","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.mam.2012.07.002","article-title":"SLC6 transporters: structure, function, regulation, disease association and therapeutics","volume":"34","author":"Pramod","year":"2013","journal-title":"Mol. Aspects Med."},{"issue":"June (2)","key":"10.1016\/j.phrs.2018.09.009_bib0070","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0031-6997(25)06783-3","article-title":"International union of pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)","volume":"46","author":"Hoyer","year":"1994","journal-title":"Pharmacol. Rev."},{"issue":"April (4)","key":"10.1016\/j.phrs.2018.09.009_bib0075","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0091-3057(01)00746-8","article-title":"Molecular, pharmacological and functional diversity of 5-HT receptors","volume":"71","author":"Hoyer","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"March (2)","key":"10.1016\/j.phrs.2018.09.009_bib0080","first-page":"256","article-title":"Expression of 5-Hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves","volume":"9","author":"Roy","year":"2000","journal-title":"J. Heart Valve Dis."},{"issue":"August (8)","key":"10.1016\/j.phrs.2018.09.009_bib0085","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2460\/ajvr.67.8.1307","article-title":"Genomic expression patterns of mitral valve tissues from dogs with degenerative mitral valve disease","volume":"67","author":"Oyama","year":"2006","journal-title":"Am. J. Vet. Res."},{"issue":"May (5)","key":"10.1016\/j.phrs.2018.09.009_bib0090","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1369\/jhc.4A6500.2005","article-title":"5-hydroxytryptamine (5HT) receptors in the heart valves of Cynomolgus monkeys and sprague-dawley rats","volume":"53","author":"Elangbam","year":"2005","journal-title":"J. Histochem. Cytochem."},{"issue":"4\u20135","key":"10.1016\/j.phrs.2018.09.009_bib0095","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.etp.2008.03.005","article-title":"5-hydroxytryptamine (5HT)-Induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in sprague-dawley rats","volume":"60","author":"Elangbam","year":"2008","journal-title":"Exp. Toxicol. Pathol."},{"issue":"January (1)","key":"10.1016\/j.phrs.2018.09.009_bib0100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0026-895X(24)26444-0","article-title":"Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine","volume":"57","author":"Fitzgerald","year":"2000","journal-title":"Mol. Pharmacol."},{"issue":"June (6)","key":"10.1016\/j.phrs.2018.09.009_bib0105","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1124\/mol.63.6.1223","article-title":"3,4-Methylenedioxymethamphetamine (MDMA, \u2018Ecstasy\u2019) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro","volume":"63","author":"Setola","year":"2003","journal-title":"Mol. Pharmacol."},{"issue":"December (6)","key":"10.1016\/j.phrs.2018.09.009_bib0110","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/S0002-9440(10)64497-5","article-title":"Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells","volume":"161","author":"Xu","year":"2002","journal-title":"Am. J. Pathol."},{"issue":"avril (1)","key":"10.1016\/j.phrs.2018.09.009_bib0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.tvjl.2015.02.021","article-title":"Gene network and canonical pathway analysis in canine myxomatous mitral valve disease: a microarray study","volume":"204","author":"Lu","year":"2015","journal-title":"Vet. J."},{"issue":"August (4)","key":"10.1016\/j.phrs.2018.09.009_bib0120","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.carpath.2012.11.001","article-title":"Emerging pathogenic mechanisms in human myxomatous mitral valve: lessons from past and novel data","volume":"22","author":"Hulin","year":"2013","journal-title":"Cardiovasc. Pathol."},{"issue":"December","key":"10.1016\/j.phrs.2018.09.009_bib0125","article-title":"Serotonin receptor 2B signaling with interstitial cell activation and leaflet remodeling in degenerative mitral regurgitation","author":"Driesbaugh","year":"2017","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"January (1)","key":"10.1016\/j.phrs.2018.09.009_bib0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/CIRCULATIONAHA.105.554667","article-title":"Deficiency of the 5-Hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice","volume":"113","author":"Mekontso-Dessap","year":"2006","journal-title":"Circulation"},{"issue":"April (4)","key":"10.1016\/j.phrs.2018.09.009_bib0135","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/01.CIR.87.4.1188","article-title":"Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 Patients","volume":"87","author":"Pellikka","year":"1993","journal-title":"Circulation"},{"issue":"October (19)","key":"10.1016\/j.phrs.2018.09.009_bib0140","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/heartjnl-2017-311261","article-title":"Carcinoid heart disease","volume":"103","author":"Hassan","year":"2017","journal-title":"Heart"},{"issue":"February (2)","key":"10.1016\/j.phrs.2018.09.009_bib0145","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1161\/01.CIR.77.2.264","article-title":"Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities","volume":"77","author":"Lundin","year":"1988","journal-title":"Circulation"},{"issue":"avril (7)","key":"10.1016\/j.phrs.2018.09.009_bib0150","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/cncr.11226","article-title":"Carcinoid heart disease","volume":"97","author":"Zuetenhorst","year":"2003","journal-title":"Cancer"},{"issue":"April (5)","key":"10.1016\/j.phrs.2018.09.009_bib0155","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.amjcard.2010.12.025","article-title":"Risk factors for the development and progression of carcinoid heart disease","volume":"107","author":"Bhattacharyya","year":"2011","journal-title":"Am. J. Cardiol."},{"issue":"October (4)","key":"10.1016\/j.phrs.2018.09.009_bib0160","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0735-1097(98)00354-4","article-title":"Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease","volume":"32","author":"Denney","year":"1998","journal-title":"J. Am. Coll. Cardiol."},{"issue":"January (1)","key":"10.1016\/j.phrs.2018.09.009_bib0165","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"January (3)","key":"10.1016\/j.phrs.2018.09.009_bib0170","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/ERC-17-0455","article-title":"Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial","volume":"25","author":"Pavel","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"issue":"April (8)","key":"10.1016\/j.phrs.2018.09.009_bib0175","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1158\/1078-0432.CCR-08-2346","article-title":"Development and characterization of a novel in vivo model of carcinoid syndrome","volume":"15","author":"Jackson","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"June (1)","key":"10.1016\/j.phrs.2018.09.009_bib0180","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jss.2005.01.003","article-title":"A mouse model of carcinoid syndrome and heart disease","volume":"126","author":"Musunuru","year":"2005","journal-title":"J. Surg. Res."},{"issue":"March (12)","key":"10.1016\/j.phrs.2018.09.009_bib0185","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1161\/01.CIR.0000159356.42064.48","article-title":"Long-term serotonin administration induces heart valve disease in rats","volume":"111","author":"Gustafsson","year":"2005","journal-title":"Circulation"},{"issue":"September (3)","key":"10.1016\/j.phrs.2018.09.009_bib0190","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s12012-009-9046-2","article-title":"Dose dependency and reversibility of serotonin-induced valvular heart disease in rats","volume":"9","author":"Droogmans","year":"2009","journal-title":"Cardiovasc. Toxicol."},{"issue":"October (1\u20133)","key":"10.1016\/j.phrs.2018.09.009_bib0195","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.regpep.2007.02.009","article-title":"Long-term serotonin effects in the rat are prevented by terguride","volume":"143","author":"Hauso","year":"2007","journal-title":"Regul. Pept."},{"issue":"February","key":"10.1016\/j.phrs.2018.09.009_bib0200","first-page":"1","article-title":"Elevated serotonin interacts with Angiotensin-II to result in altered valve interstitial cell contractility and remodeling","author":"Perez","year":"2017","journal-title":"Cardiovasc. Eng. Technol."},{"issue":"February (7)","key":"10.1016\/j.phrs.2018.09.009_bib0205","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1056\/NEJM196602172740701","article-title":"Fibrotic disorders associated with methysergide therapy for headache","volume":"274","author":"Graham","year":"1966","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.09.009_bib0210","first-page":"79","article-title":"Cardiac and pulmonary fibrosis during methysergide therapy for headache","volume":"78","author":"Graham","year":"1967","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"issue":"August (9)","key":"10.1016\/j.phrs.2018.09.009_bib0215","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"August (9689)","key":"10.1016\/j.phrs.2018.09.009_bib0220","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(09)60252-X","article-title":"Drug-induced fibrotic valvular heart disease","volume":"374","author":"Bhattacharyya","year":"2009","journal-title":"Lancet (London, England)"},{"issue":"January (1)","key":"10.1016\/j.phrs.2018.09.009_bib0225","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"December (23)","key":"10.1016\/j.phrs.2018.09.009_bib0230","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"issue":"March (3)","key":"10.1016\/j.phrs.2018.09.009_bib0235","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1183\/09031936.00086308","article-title":"Fenfluramine-like cardiovascular side-effects of benfluorex","volume":"33","author":"Boutet","year":"2009","journal-title":"Eur. Respir. J."},{"issue":"d\u00e9cembre (12)","key":"10.1016\/j.phrs.2018.09.009_bib0240","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/pds.2044","article-title":"Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus","volume":"19","author":"Weill","year":"2010","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"November (9)","key":"10.1016\/j.phrs.2018.09.009_bib0245","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.amjcard.2007.06.045","article-title":"Possible association between 3,4-Methylenedioxymethamphetamine abuse and valvular heart disease","volume":"100","author":"Droogmans","year":"2007","journal-title":"Am. J. Cardiol."},{"issue":"September (17)","key":"10.1016\/j.phrs.2018.09.009_bib0250","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1093\/eurheartj\/ehm263","article-title":"In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology","volume":"28","author":"Droogmans","year":"2007","journal-title":"Eur. Heart J."},{"issue":"June (6)","key":"10.1016\/j.phrs.2018.09.009_bib0255","article-title":"Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study","volume":"296","author":"Droogmans","year":"2009","journal-title":"Am. J. Physiol. - Heart Circ. Physiol."},{"issue":"July (1)","key":"10.1016\/j.phrs.2018.09.009_bib0260","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1751-0147-55-52","article-title":"A retrospective study of clinical signs and epidemiology of chronic valve disease in a group of 207 dachshunds in Poland","volume":"55","author":"Garncarz","year":"2013","journal-title":"Acta Vet. Scand."},{"issue":"October (2)","key":"10.1016\/j.phrs.2018.09.009_bib0265","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.rvsc.2009.01.009","article-title":"Immunohistochemical characterization of the extracellular matrix in normal mitral valves and in chronic valve disease (Endocardiosis) in dogs","volume":"87","author":"Aupperle","year":"2009","journal-title":"Res. Vet. Sci."},{"issue":"February (1)","key":"10.1016\/j.phrs.2018.09.009_bib0270","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1939-1676.2011.00860.x","article-title":"Survival characteristics and prognostic variables of dogs with preclinical chronic degenerative mitral valve disease attributable to myxomatous degeneration","volume":"26","author":"Borgarelli","year":"2012","journal-title":"J. Vet. Intern. Med."},{"issue":"April (2)","key":"10.1016\/j.phrs.2018.09.009_bib0275","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1939-1676.2007.tb02958.x","article-title":"Chordae tendineae rupture in dogs with degenerative mitral valve disease: prevalence, survival, and prognostic factors (114 cases, 2001\u20132006)","volume":"21","author":"Serres","year":"2007","journal-title":"J. Vet. Intern. Med."},{"issue":"March (1)","key":"10.1016\/j.phrs.2018.09.009_bib0280","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jvc.2011.12.001","article-title":"Signaling pathways in mitral valve degeneration","volume":"14","author":"Orton","year":"2012","journal-title":"J. Vet. Cardiol., The Mitral Valve"},{"issue":"March (1)","key":"10.1016\/j.phrs.2018.09.009_bib0285","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jvc.2012.01.005","article-title":"Pathology, protein expression and signaling in myxomatous mitral valve degeneration: comparison of dogs and humans","volume":"14","author":"Aupperle","year":"2012","journal-title":"J. Vet. Cardiol., The Mitral Valve"},{"issue":"September (Suppl_1)","key":"10.1016\/j.phrs.2018.09.009_bib0290","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/jhered\/esr041","article-title":"Identification of 2 loci associated with development of myxomatous mitral valve disease in cavalier king Charles Spaniels","volume":"102","author":"Madsen","year":"2011","journal-title":"J. Hered."},{"issue":"December (6)","key":"10.1016\/j.phrs.2018.09.009_bib0295","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/j.1939-1676.2009.0378.x","article-title":"Serum serotonin concentrations in dogs with degenerative mitral valve disease","volume":"23","author":"Arndt","year":"2009","journal-title":"J. Vet. Intern. Med."},{"issue":"October (5)","key":"10.1016\/j.phrs.2018.09.009_bib0300","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/jvim.12420","article-title":"Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease","volume":"28","author":"Cremer","year":"2014","journal-title":"J. Vet. Intern. Med."},{"issue":"June","key":"10.1016\/j.phrs.2018.09.009_bib0305","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.rvsc.2015.03.020","article-title":"Alpha-smooth muscle actin and serotonin receptors 2A and 2B in dogs with myxomatous mitral valve disease","volume":"100","author":"Cremer","year":"2015","journal-title":"Res. Vet. Sci."},{"issue":"d\u00e9cembre (3)","key":"10.1016\/j.phrs.2018.09.009_bib0310","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jvc.2010.06.002","article-title":"Serotonin transmembrane transporter is down-regulated in late-stage canine degenerative mitral valve disease","volume":"12","author":"Scruggs","year":"2010","journal-title":"J. Vet. Cardiol."},{"issue":"September (11)","key":"10.1016\/j.phrs.2018.09.009_bib0315","first-page":"1843","article-title":"Serotonin transport and serotonin transporter-mediated antidepressant recognition are controlled by 5-HT2B receptor signaling in serotonergic neuronal cells","volume":"20","author":"Launay","year":"2006","journal-title":"FASEB J."},{"issue":"January (1)","key":"10.1016\/j.phrs.2018.09.009_bib0320","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4142\/jvs.2018.19.1.129","article-title":"Polymorphism in the serotonin transporter protein gene in maltese dogs with degenerative mitral valve disease","volume":"19","author":"Lee","year":"2018","journal-title":"J. Vet. Sci."},{"issue":"August (8)","key":"10.1016\/j.phrs.2018.09.009_bib0325","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1114\/B:ABME.0000036640.11387.4b","article-title":"Design and hydrodynamic evaluation of a novel pulsatile bioreactor for biologically active heart valves","volume":"32","author":"Hildebrand","year":"2004","journal-title":"Ann. Biomed. Eng."},{"issue":"July (1)","key":"10.1016\/j.phrs.2018.09.009_bib0330","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.athoracsur.2011.03.084","article-title":"Aortic valve cyclic stretch causes increased remodeling activity and enhanced serotonin receptor responsiveness","volume":"92","author":"Balachandran","year":"2011","journal-title":"Ann. Thorac. Surg."},{"issue":"June (3)","key":"10.1016\/j.phrs.2018.09.009_bib0335","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.carpath.2011.07.005","article-title":"Elevated cyclic stretch and serotonin result in altered aortic valve remodeling via a mechanosensitive 5-HT(2A) receptor-dependent pathway","volume":"21","author":"Balachandran","year":"2012","journal-title":"Cardiovasc. Pathol."},{"issue":"March (1)","key":"10.1016\/j.phrs.2018.09.009_bib0340","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jvc.2011.12.002","article-title":"Static and cyclic tensile strain induce myxomatous effector proteins and serotonin in canine mitral valves","volume":"14","author":"Lacerda","year":"2012","journal-title":"J. Vet. Cardiol., The Mitral Valve"},{"issue":"February (10)","key":"10.1016\/j.phrs.2018.09.009_bib0345","doi-asserted-by":"crossref","first-page":"H1983","DOI":"10.1152\/ajpheart.00987.2011","article-title":"Local serotonin mediates cyclic strain-induced phenotype transformation, matrix degradation, and glycosaminoglycan synthesis in cultured sheep mitral valves","volume":"302","author":"Lacerda","year":"2012","journal-title":"Am. J. Physiol.-Heart Circ. Physiol."},{"issue":"October (4)","key":"10.1016\/j.phrs.2018.09.009_bib0350","doi-asserted-by":"crossref","first-page":"H1354","DOI":"10.1152\/ajpheart.00570.2009","article-title":"Serotonin produces monoamine oxidase-dependent oxidative stress in human heart valves","volume":"297","author":"Pe\u00f1a-Silva","year":"2009","journal-title":"Am. J. Physiol.-Heart Circ. Physiol."},{"issue":"July (7)","key":"10.1016\/j.phrs.2018.09.009_bib0355","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/dvdy.22346","article-title":"Expression of the familial cardiac valvular dystrophy gene, Filamin-A, during heart morphogenesis","volume":"239","author":"Norris","year":"2010","journal-title":"Dev. Dyn."},{"issue":"December (6)","key":"10.1016\/j.phrs.2018.09.009_bib0360","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s12265-011-9308-9","article-title":"Filamin-a-related myxomatous mitral valve dystrophy: genetic, echocardiographic and functional aspects","volume":"4","author":"Lardeux","year":"2011","journal-title":"J. Cardiovasc. Transl. Res."},{"issue":"October (1)","key":"10.1016\/j.phrs.2018.09.009_bib0365","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/cvr\/cvs238","article-title":"Developmental basis for Filamin-A-associated myxomatous mitral valve disease","volume":"96","author":"Sauls","year":"2012","journal-title":"Cardiovasc. Res."},{"issue":"September (3)","key":"10.1016\/j.phrs.2018.09.009_bib0370","first-page":"233","article-title":"MVP-associated filamin a mutations affect FlnA-PTPN12 (PTP-PEST) interactions","volume":"2","author":"Duval","year":"2015","journal-title":"J. Cardiovasc. Dev. Dis."},{"issue":"November (5)","key":"10.1016\/j.phrs.2018.09.009_bib0375","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.yjmcc.2012.08.012","article-title":"5-HT2B antagonism arrests non-canonical TGF-B1-induced valvular myofibroblast differentiation","volume":"53","author":"Hutcheson","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"November (6)","key":"10.1016\/j.phrs.2018.09.009_bib0380","first-page":"827","article-title":"Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects","volume":"10","author":"Rajamannan","year":"2001","journal-title":"J. Heart Valve Dis."},{"issue":"September (3)","key":"10.1016\/j.phrs.2018.09.009_bib0385","doi-asserted-by":"crossref","first-page":"988","DOI":"10.2353\/ajpath.2009.081101","article-title":"Fenfluramine disrupts the mitral valve interstitial cell response to serotonin","volume":"175","author":"Connolly","year":"2009","journal-title":"Am. J. Pathol."},{"issue":"September (5)","key":"10.1016\/j.phrs.2018.09.009_bib0390","first-page":"626","article-title":"Organ culture as a tool to identify early mechanisms of serotonergic valve disease","volume":"19","author":"Barzilla","year":"2010","journal-title":"J. Heart Valve Dis."},{"issue":"February (2)","key":"10.1016\/j.phrs.2018.09.009_bib0395","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1124\/jpet.111.187906","article-title":"Antiserotonergic properties of terguride in blood vessels, platelets, and valvular interstitial cells","volume":"340","author":"Kekewska","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"December (6)","key":"10.1016\/j.phrs.2018.09.009_bib0400","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0002-9440(10)64489-6","article-title":"Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth Factor-Beta1 via G-protein signal transduction in aortic valve interstitial cells","volume":"161","author":"Jian","year":"2002","journal-title":"Am. J. Pathol."},{"issue":"March (2)","key":"10.1016\/j.phrs.2018.09.009_bib0405","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00001573-200403000-00013","article-title":"Angiogenic modulators in valve development and disease: does valvular disease recapitulate developmental signaling pathways?","volume":"19","author":"Shworak","year":"2004","journal-title":"Curr. Opin. Cardiol."},{"issue":"4","key":"10.1016\/j.phrs.2018.09.009_bib0410","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.bbrc.2014.03.014","article-title":"Losartan Inhibits Endothelial-to-Mesenchymal Transformation in Mitral Valve Endothelial Cells by Blocking Transforming Growth Factor-\u03b2-Induced Phosphorylation of ERK","volume":"446","author":"Wylie-Sears","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"October (4)","key":"10.1016\/j.phrs.2018.09.009_bib0415","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1124\/mol.109.058057","article-title":"Parallel functional activity profiling reveals valvulopathogens are potent 5-Hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment","volume":"76","author":"Huang","year":"2009","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2018.09.009_bib0420","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/0192623317690609","article-title":"Regulatory forum review*: utility of in vitro secondary pharmacology data to assess risk of drug-induced valvular heart disease in humans: regulatory considerations","volume":"45","author":"Papoian","year":"2017","journal-title":"Toxicol. Pathol."},{"issue":"May (6132)","key":"10.1016\/j.phrs.2018.09.009_bib0425","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1126\/science.1232808","article-title":"Structural features for functional selectivity at serotonin receptors","volume":"340","author":"Wacker","year":"2013","journal-title":"Science (New York, N.Y.)"},{"issue":"June","key":"10.1016\/j.phrs.2018.09.009_bib0430","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pharmthera.2015.01.009","article-title":"Structure and function of serotonin g protein-coupled receptors","volume":"150","author":"McCorvy","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"December (3)","key":"10.1016\/j.phrs.2018.09.009_bib0435","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1124\/jpet.113.207670","article-title":"Kinetics of 5-HT2B receptor signaling: profound agonist-dependent effects on signaling onset and duration","volume":"347","author":"Unett","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"April (4)","key":"10.1016\/j.phrs.2018.09.009_bib0440","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1124\/mol.106.033035","article-title":"The A1b-adrenoceptor exists as a higher-order oligomer: effective oligomerization is required for receptor maturation, surface delivery, and function","volume":"71","author":"Lopez-Gimenez","year":"2007","journal-title":"Mol. Pharmacol."},{"issue":"November (5)","key":"10.1016\/j.phrs.2018.09.009_bib0445","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1124\/mol.108.048272","article-title":"Morphine desensitization, internalization, and down-regulation of the \u03bc opioid receptor is facilitated by serotonin 5-hydroxytryptamine2A receptor coactivation","volume":"74","author":"Lopez-Gimenez","year":"2008","journal-title":"Mol. Pharmacol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818305875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818305875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:55:00Z","timestamp":1760910900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661818305875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":89,"alternative-id":["S1043661818305875"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2018.09.009","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734005065.793585441","asserted-by":"object"}]},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serotonin contribution to cardiac valve degeneration: new insights for novel therapies?","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2018.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}